New York State Common Retirement Fund Decreases Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

New York State Common Retirement Fund cut its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 8.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,755 shares of the company's stock after selling 9,880 shares during the quarter. New York State Common Retirement Fund owned about 0.30% of TransMedics Group worth $15,819,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Fidelis Capital Partners LLC acquired a new position in TransMedics Group during the first quarter worth $35,000. International Assets Investment Management LLC acquired a new position in shares of TransMedics Group during the 2nd quarter valued at about $47,000. USA Financial Formulas purchased a new stake in shares of TransMedics Group in the third quarter valued at about $55,000. J.Safra Asset Management Corp increased its position in TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company's stock worth $67,000 after purchasing an additional 383 shares during the last quarter. Finally, Signaturefd LLC raised its stake in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company's stock worth $67,000 after purchasing an additional 93 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TMDX shares. Morgan Stanley increased their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the company an "equal weight" rating in a research note on Monday, July 15th. Canaccord Genuity Group cut their target price on TransMedics Group from $169.00 to $109.00 and set a "buy" rating for the company in a research note on Tuesday, October 29th. Baird R W upgraded TransMedics Group to a "strong-buy" rating in a report on Tuesday, September 24th. Piper Sandler reissued an "overweight" rating and set a $180.00 price objective on shares of TransMedics Group in a research report on Tuesday, October 29th. Finally, Stephens upped their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $144.80.

TransMedics Group Stock Up 4.0 %

NASDAQ:TMDX traded up $3.35 during midday trading on Wednesday, reaching $86.35. The company had a trading volume of 1,512,693 shares, compared to its average volume of 948,450. The stock's fifty day simple moving average is $136.94 and its 200-day simple moving average is $139.95. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12-month low of $55.29 and a 12-month high of $177.37. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of 88.30 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same period last year, the business earned ($0.12) EPS. The firm's revenue was up 63.7% compared to the same quarter last year. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.08 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the transaction, the insider now owns 20,843 shares of the company's stock, valued at approximately $3,089,766.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Tamer I. Khayal sold 2,958 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $3,089,766.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,208 shares of company stock worth $7,853,165. 7.00% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.